Waters AI Stock Analysis
Waters (WAZ) AI Stock Analysis
Waters
(BX Swiss:WAZ)
No summary available
Waters (WAZ) vs. iShares MSCI Switzerland ETF (EWL)
- Market Cap
- CHF 45.24B
- Dividend Yield
- ―
- Average Volume (3M)
- 3
- Price to Earnings (P/E)
- 195.9
- Beta (1Y)
- 0.16
- Revenue Growth
- 69.55%
- EPS Growth
- -79.44%
- Country
- Switzerland
- Employees
- 15,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Waters Business Overview & Revenue Model
Company Description
Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactu...
Waters Earnings Call Summary
The call was strongly positive. Highlights significantly outweighed the challenges, with double-digit organic growth, a 21% adjusted EPS increase, raised full-year revenue and EPS guidance, improving acquired-business execution, strong product and AI momentum, cost-savings progress and a constructive 2027 framework. The main negatives were limited reported growth in the acquired businesses, China DRG and channel-inventory headwinds, constrained free cash flow, elevated inventory and acquisition-related costs.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, organic constant currency revenue growth guidance was raised 140 basis points at the midpoint to 9.1% to 9.7%, with organic reported revenue expected at $3.429 billion to $3.447 billion; Biosciences and Diagnostic Solutions revenue is expected to be approximately $3.05 billion, a $5 million raise, and total reported revenue is expected to be approximately $6.479 billion to $6.497 billion, a $43 million raise at the midpoint. Full year adjusted EBIT margin is expected to be 28.2%, net interest expense $196 million, the tax rate 15.4%, and adjusted earnings per fully diluted share $14.60 to $14.70, representing year-over-year growth of 11% to 12% and 13% to 14% in constant currency. Fourth quarter organic constant currency revenue growth is expected to be 7% to 9%, organic reported revenue $984 million to $1.002 billion, Biosciences and Diagnostic Solutions revenue approximately $817 million, total reported revenue $1.801 billion to $1.819 billion, and adjusted earnings per fully diluted share $4.58 to $4.68; on a days adjusted basis, guidance reflects 9% to 11% organic growth and approximately 10% reported growth for acquired businesses. For 2027, the starting assumption is legacy Waters growing high single digits and legacy BD growing mid-single digits, combining to mid-single-digit plus organic growth, with a critical path to a high single-digit growth potential for the combined company, 100 basis points of adjusted operating margin expansion to 29.2%, low teens adjusted EPS growth, and mid-teens as the upside case; revenue synergies are underwritten at another $60 million added in 2027 over and above the $50 million in 2026.
Waters Risk Analysis
Waters disclosed 2 risk factors in its most recent earnings report. Waters reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
1 New RiskWaters Peers Comparison
Overall Rating
A78Outperform
TMO76.9Outperform
MTD75Outperform
RVTY74Outperform
DHR73Outperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | $49.04B | 34.18 | 20.47% | 0.59% | 8.60% | 19.07% | |
| 77Outperform | $259.44B | 36.87 | 13.31% | 0.26% | 8.27% | 9.59% | |
| 75Outperform | $34.59B | 37.59 | 9999.00% | ― | 6.51% | 15.03% | |
| 74Outperform | $17.24B | 68.31 | 3.50% | 0.18% | 4.56% | 13.22% | |
| 73Outperform | $163.94B | 38.08 | 8.18% | 0.65% | 5.52% | 25.53% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CH:WAZ | Waters Corp | 397.26 | 53.16 | 15.45% | |
| A | Agilent Technologies | 173.96 | 30.52 | 21.27% | |
| DHR | Danaher Corporation | 233.02 | 14.20 | 6.49% | |
| MTD | Mettler-toledo International | 1738.91 | 349.95 | 25.20% | |
| RVTY | Revvity, Inc. | 154.39 | 63.55 | 69.97% | |
| TMO | Thermo Fisher Scientific | 700.22 | 135.05 | 23.89% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
